Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States

Spremljeno u:
Bibliografski detalji
Izdano u:American Journal of Public Health vol. 100, no. 2 (Feb 2010), p. 341-348
Glavni autor: Apelberg, Benjamin J, PhD, MHS
Daljnji autori: Onicescu, Georgiana, ScM, Avila-Tang, Erika, PhD, MHS, Samet, Jonathan M, MD, MS
Izdano:
American Public Health Association
Teme:
Online pristup:Citation/Abstract
Full Text
Full Text - PDF
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

MARC

LEADER 00000nab a2200000uu 4500
001 215089875
003 UK-CbPIL
022 |a 0090-0036 
022 |a 0002-9572 
022 |a 0271-4353 
022 |a 0273-1975 
035 |a 215089875 
045 2 |b d20100201  |b d20100228 
084 |a 20019322 
084 |a 8  |2 nlm 
100 1 |a Apelberg, Benjamin J, PhD, MHS 
245 1 |a Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States 
260 |b American Public Health Association  |c Feb 2010 
513 |a Journal Article 
520 3 |a To compare potential population-wide benefits and risks, we examined the potential impact of increased nicotine replacement therapy (NRT) use for smoking cessation on future US mortality. We developed a simulation model incorporating a Monte Carlo uncertainty analysis, with data from the 2005 National Health Interview Survey and Cancer Prevention Study II. We estimated the number of avoided premature deaths from smoking attributable to increased NRT use, before and after incorporating assumptions about NRT harm. We estimate that a gradual increase in the proportion of NRT-aided quit attempts to 100% by 2025 would lead to 40000 (95% credible interval= 31000, 50000) premature deaths avoided over a 20-year period. Most avoided deaths would be attributable to lung cancer and cardiovascular disease. After we incorporated assumptions about potential risk from long-term NRT, the estimate of avoided premature deaths from all causes declined to 32000. Even after we assumed some harm from long-term NRT use, the benefits from increased cessation success far outweigh the risks. However, the projected reduction in premature mortality still reflects a small portion of the tobacco-related deaths expected over a 20-year period.   To compare potential population-wide benefits and risks, we examined the potential impact of increased nicotine replacement therapy (NRT) use for smoking cessation on future US mortality. We developed a simulation model incorporating a Monte Carlo uncertainty analysis, with data from the 2005 National Health Interview Survey and Cancer Prevention Study II. We estimated the number of avoided premature deaths from smoking attributable to increased NRT use, before and after incorporating assumptions about NRT harm. We estimate that a gradual increase in the proportion of NRT-aided quit attempts to 100% by 2025 would lead to 40,000 (95% credible interval=31,000, 50,000) premature deaths avoided over a 20-year period. Most avoided deaths would be attributable to lung cancer and cardiovascular disease. After we incorporated assumptions about potential risk from long-term NRT, the estimate of avoided premature deaths from all causes declined to 32 000. Even after we assumed some harm from long-term NRT use, the benefits from increased cessation success far outweigh the risks. However, the projected reduction in premature mortality still reflects a small portion of the tobacco-related deaths expected over a 20-year period. 
650 2 2 |a Computer Simulation 
650 2 2 |a Cost-Benefit Analysis 
650 2 2 |a Humans 
650 2 2 |a Monte Carlo Method 
650 2 2 |a Nicotine  |x adverse effects 
650 1 2 |a Nicotine  |x therapeutic use 
650 2 2 |a Risk 
650 2 2 |a Smoking  |x mortality 
650 1 2 |a Smoking  |x prevention & control 
650 1 2 |a Smoking Cessation 
650 2 2 |a Tobacco, Smokeless  |x adverse effects 
650 2 2 |a United States  |x epidemiology 
651 4 |a United States--US 
653 |a Mortality 
653 |a Cancer 
653 |a Monte Carlo simulation 
653 |a Risk factors 
653 |a Larynx 
653 |a Confidence intervals 
653 |a Apoptosis 
653 |a Population 
653 |a Womens health 
653 |a Lung cancer 
653 |a Success 
653 |a Gender 
653 |a Cardiovascular disease 
653 |a Tobacco 
653 |a Age groups 
653 |a Disease prevention 
653 |a Abstinence 
653 |a Cohort analysis 
653 |a Public health 
653 |a Cardiovascular diseases 
653 |a Premature mortality 
653 |a Long term 
653 |a Medical treatment 
653 |a Benefits 
653 |a Simulation 
653 |a Deaths 
653 |a Nicotine replacement therapy 
653 |a Uncertainty 
653 |a Therapy 
653 |a Social 
700 1 |a Onicescu, Georgiana, ScM 
700 1 |a Avila-Tang, Erika, PhD, MHS 
700 1 |a Samet, Jonathan M, MD, MS 
773 0 |t American Journal of Public Health  |g vol. 100, no. 2 (Feb 2010), p. 341-348 
786 0 |d ProQuest  |t ABI/INFORM Global 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/215089875/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/215089875/fulltext/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/215089875/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch